What question did this study set out to answer?

This review aims to synthesize evidence on differentiation therapy in acute myeloid leukemia, focusing on mechanisms and efficacy.

February 14, 2026Open Access

Differentiation Syndrome in Acute Myeloid Leukemia: Molecular Mechanisms, Clinical Spectrum, and Emerging Therapeutic Paradigms

Puntos clave

This review aims to synthesize evidence on differentiation therapy in acute myeloid leukemia, focusing on mechanisms and efficacy.
Conducted a narrative review of preclinical and clinical trials on differentiation therapy.
Focused on targeted agents including IDH1/2, FLT3, and menin inhibitors.
Employed SANRA guidelines for literature search from PubMed (2010–September 2025).
IDH1/2 inhibitors show overall response rates (ORRs) of 30–94% in AML with differentiation syndrome (DS) present in 10–19%.
Menin inhibitors achieve ORRs of 33–88% in KMT2A-rearranged or NPM1-mutated AML, with DS in 10–25%.
FLT3 inhibitors improve survival in FLT3-mutated AML, with DS in 1–5%.
Resistance mutations are identified as a barrier to treatment durability.

Resumen

Acute myeloid leukemia (AML) is characterized by differentiation arrest, driving blast proliferation, and abnormal blood formation. While differentiation therapy revolutionized acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), its extension into non-APL AML has been limited until recent targeted agents. This narrative review synthesizes preclinical and clinical evidence into differentiation-inducing therapy, with a focus on IDH1/2, FLT3 and menin inhibitors. Following SANRA guidelines, we searched PubMed (2010–September 2025) for clinical trials and key preclinical studies, with particular attention to the molecular mechanism of differentiation induction, clinical efficacy, and the management of differentiation syndrome (DS). IDH1/2 inhibitors (ivosidenib, enasidenib, olutasidenib) yield overall response rates (ORRs) of 30–94% in AML with DS in 10–19%. Menin inhibitors (revumenib, ziftomenib, enzomenib, bleximenib) achieve ORRs of 33–88% in KMT2A-rearranged or NPM1-mutated AML, with DS in 10–25% and QT prolongation as key toxicities. FLT3 inhibitors (gilteritinib, quizartinib) improve survival in FLT3-mutated AML with DS in 1–5%. Resistance mutations limit durability and combinations enhance efficacy. Differentiation therapy represents a paradigm shift towards non-cytotoxic AML management. Improved recognition of DS and rational combination approaches will be essential to maximize the therapeutic benefit. Future research should address mechanisms of resistance and biomarkers to achieve cures beyond APL.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo